In the modified intent-to-treat population ( MEC = @ ; HEC = @ ) , both APF@ doses were noninferior to palonosetron in preventing acute CINV after MEC ( CRs @ % -LSB- -@ , @ -RSB- and @ % -LSB- -@ , @ -RSB- , respectively , vs. @ % palonosetron ) and after HEC ( CRs @ % -LSB- -@ , @ -RSB- and @ % -LSB- -@ , @ -RSB- , respectively , vs. @ % palonosetron ) .